FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results-Reference-Cited by-同舟云学术

FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results

Published:2000-05 Issue:8 Volume:36 Page:966-975
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Pacini P.,Rinaldini M.,Algeri R.,Guarneri A.,Tucci E.,Barsanti G.,Neri B.,Bastiani P.,Marzano S.,Fallai C.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference35 articles.

1. Effect of lonidamine on the cytotoxic activity of cisplatin, mitomycin C and BCNU in human ovarian and colon carcinoma cells;Zaffaroni;Int. J. Oncol.,1994

2. Lonidamine;Forster;Carcinogenesis,1990

3. In vitro and in vivo potentiation by lonidamine of the antitumor effect of Adriamycin;Zupi;Anticancer Res.,1986

4. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells;Floridi;J. Natl. Cancer Inst.,1981

5. Effects of Lonidamine alone or combined with hyperthermia in some experimental cell and tumor systems;Silvestrini;Br. J. Cancer,1983

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NEAT1 repression by MED12 creates chemosensitivity in p53 wild‐type breast cancer cells;The FEBS Journal;2024-02-21

2. The effect of lactate dehydrogenase inhibitors on proliferation, motility and invasion of breast cancer cells in vitro highlights a new role for lactate;Molecular Medicine Reports;2023-11-22

3. Cancer metabolism and its interplay with pH;pH Deregulation as the Eleventh Hallmark of Cancer;2023

4. Is antitumor Pt(IV) complex containing two axial lonidamine ligands a true dual- or multi-action prodrug?;Metallomics;2022

5. Chemotherapeutic Protocols for the Treatment of Breast Cancer;Chemotherapy Protocols and Infusion Sequence;2022